Posthoc analysis assesses exposure–efficacy of subcutaneous and intravenous vedolizumab in ulcerative colitis and Crohn's disease, clarifying dosing strategies across formulations.
Background and aims This posthoc analysis of the GEMINI and VISIBLE studies in ulcerative colitis (UC) and Crohn's Disease (CD) assessed exposure−efficacy of vedolizumab intravenous (IV) and subcutaneous (SC).
No takes yet. Share an insight, caveat, or question.
DʼHaens et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: